Speaker illustration

Mr Sho Nakao

Kansai Rosai Hospital, Amagasaki (Japan)

Member of:

European Society of Cardiology

Dual pathway inhibitor therapy switched from dual antiplatelet therapy reduces risk of recurrent in-stent occlusion after endovascular therapy for femoropopliteal in-stent occlusion.

Event: ESC Congress 2023

Topic: Pharmacotherapy

Session: Arterial occlusive disease: a chronic pandemic needing attention to detail

Thumbnail